CD20 positivity in classical Hodgkin′s lymphoma: Diagnostic challenge or targeting opportunity

Barakzai, Muhammad Abrar; Pervez, Shahid

doi:10.4103/0377-4929.44952

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have demonstrated positivity for CD20, ranging from 5% to 50%. In this study, 17.5% (7/40) patients of CHL were immunoreactive for CD20 which is similar to that reported by Barakzai and Pervez[ 5 ] (19.8%). CD15 negativity with CD20 positivity was seen in 2 (5%) patients of otherwise typical CHL which is also similar to that reported by Barakzai and Pervez[ 5 ] (7.7%) [ Table 6 ].…”

Section: Discussionsupporting

confidence: 90%

“…There was an overall male predominance with male:female ratio of 2.6:1, (CHL n = 189, male - 136/189, 71.9%:female - 53/189, 28%; NLPHL, n = 6, male - 6 [(100%]) similar to that reported by Patkar et al . [ 4 ] (CHL, male - 71%, female - 29%; NLPHL male - 78%, female - 22%) and Barakzai and Pervez[ 5 ] (CHL, male - 70, [76.9%]:female - 21 [23.%]).…”

Section: Discussionmentioning

confidence: 99%

“…Patkar et al [4] (%) Barakzai et al [5] (%) Present study (%) [2] (%) Patkar et al study [4] (%) Barakzai et al study [5]…”

Section: Histologic Typesmentioning

confidence: 99%

See 2 more Smart Citations

Hodgkin lymphoma: A clinicopathological and immunophenotypic study

Konkay

Paul

Uppin

et al. 2016

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Introduction:The diagnosis of Hodgkin lymphoma (HL) is defined in terms of its microscopic appearance (histology) and the expression of cell surface markers (immunophenotype).Aims and objectives:This study aims to analyze the clinical features, histomorphology, and immunoprofile of over 200 patients of HL diagnosed over a period of 4 years at our institute and to determine relative frequency of various histological subtypes (based on WHO classification) in relation to age and sex distribution in this part of the country.Materials and Methods:All HL cases diagnosed between January 2006 and December 2009 were retrieved from hospital records. The histopathology of both lymph node and bone marrow biopsy (where ever available) along with immunohistochemistry (CD15, CD30, CD20, and ALK) were reviewed.Results:There was a bimodal age distribution. HL affected people a decade earlier than in the western population. The most common presenting complaint was cervical lymphadenopathy. Mixed cellularity was the most frequent subtype (67%), followed by nodular sclerosing subtype (23.5%). Group A (CD15+, CD30+, CD20−), which represents the archetypical immunophenotype of classical HL (CHL) was the most common type (60.6%). The number of CD15 negative CHL was 35.8% and CD20 positive CHL was 17.5%. CD15 negativity with CD20 positivity was seen in 5% CHL. One out of seven CD20 positive CHL patients showed relapse.Conclusion:In this paper, we have discussed in detail about various clinical and histopathological parameters of HL and their relative frequency in various histological subtypes. This paper is being presented as it is a rather large study from India taking into consideration the clinical, pathologic, and immunophenotypic profile of the patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hodgkin lymphoma: A clinicopathological and immunophenotypic study

Konkay

Paul

Uppin

et al. 2016

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…Mature B-cell neoplasms comprise >90% of all lymphoid neoplasms along with precursor B lymphoblastic lymphoma /leukemia and classic Hodgkin lymphoma (Dong et al, 2008;Swerdlowet al, 2010) These neoplasms comprise of neoplastic B cells at a wide range of differentiation, from precursor B cells in the B-cell maturation pathway with only partial expression of pan-B-cell antigens to late-stage B cells undergoing plasma cell differentiation with someloss of B-cell signatures (Dong et al, 2008). Classic Hodgkin lymphoma, traditionally considered a separate entity is now considered as a neoplasm of B cell lineage which creates a greater overlap between classic Hodgkin lymphoma and many forms of B cell malignancies (Swerdlowet al, 2010;Barakzai et al, 2009;Sultan et al, 2016). Recognition of the B-cell lineage is crucial for diagnosis and classification of these lymphomas which is greatly dependent on immunohistochemistry (Jensenetal., 2007).…”

Section: Introductionmentioning

confidence: 99%

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Khan

Ahmad

Kayani

et al. 2018

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: B-cell malignancies including Precursor B-cell lymphoblastic lymphoma/leukemia and Hodgkin Lymphoma show a wide spectrum of B-cell differentiation from early stage B-cell precursors to mature B-cells ending in terminal differentiation to plasma cells. Pan-B-cell antigens routinely used for the diagnosis of B-cell lymphoma, include CD19, CD20, CD22 and CD79a.PAX-5 protein, also known as B-cell-specific activation protein is a B-cell-specific transcription factor; essential for commitment and functional maintenance used in the diagnosis of B cell Hodgkin and non-Hodgkin lymphoma. PAX-5 show nuclear positivity in B cell lymphomas and moderate (dim) positivity in Hodgkinlymphoma Reed Sternberg cells make this marker ideal for diagnosing B cell malignances. Objective: To determine the expression of PAX-5 in B cell Hodgkin and non-Hodgkin Lymphoma in order to improve the diagnosis of B-cell lymphomas. Methods: In this Prospective study, all the cases of B cell lymphoma diagnosed at The Aga Khan University Hospital, Karachi from July 2010 to July 2011were included. A panel of Immunohistochemical stain was performed in all cases along with additional PAX- 5 stain with appropriate controls. Results: Total 125 cases were included. Hodgkin Lymphoma (Mixed cellularity) was the commonest B-cell lymphoma subtype, 32 (25%) cases. Other common subtypes included Hodgkin lymphoma (Nodular sclerosis subtype), diffuse large B-cell lymphoma and B lymphoblastic lymphoma. Conclusion: This study demonstrates that PAX-5 is the most sensitive and reliable immuhohistochemicalmarker in the diagnosis of B cell Hodgkin and non-Hodgkin lymphoma.

show abstract

“…It is widely expressed in many B cell malignancies, including B cell lymphoma and B cell chronic lymphocytic leukemia [87, 88]. CD20 expression has also been found in some forms of HL [89]. While the expression of some surface proteins can provide prognostic information in patients, expression of CD20 does not correlate with disease severity or patient prognosis.…”

Section: Preclinical Imaging Of Lymphoma Using Radiolabeled Antibodiesmentioning

confidence: 99%

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

England

Cai

2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Lymphoma is a complex disease that arises from cells of the immune system with an intricate pathology. While lymphoma may be classified as Hodgkin or non-Hodgkin, each type of tumor is genetically and phenotypically different and highly invasive tissue biopsies are the only method to investigate these differences. Noninvasive imaging strategies, such as immunoPET, can provide a vital insight into disease staging, monitoring treatment response in patients, and dose planning in radioimmunotherapy. ImmunoPET imaging with radiolabeled antibody-based tracers may also assist physicians in optimizing treatment strategies and enhancing patient stratification. Currently, there are two common biomarkers for molecular imaging of lymphoma, CD20 and CD30, both of which have been considered for investigation in preclinical imaging studies. In this review, we examine the current status of both preclinical and clinical imaging of lymphoma using radiolabeled antibodies. Additionally, we briefly investigate the role of radiolabeled antibodies in lymphoma therapy. As radiolabeled antibodies play critical roles in both imaging and therapy of lymphoma, the development of novel antibodies and the discovery of new biomarkers may greatly affect lymphoma imaging and therapy in the future.

show abstract

CD20 positivity in classical Hodgkin′s lymphoma: Diagnostic challenge or targeting opportunity

Cited by 7 publications

References 0 publications

Hodgkin lymphoma: A clinicopathological and immunophenotypic study

Hodgkin lymphoma: A clinicopathological and immunophenotypic study

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

Contact Info

Product

Resources

About